EXPERIENCE OF THE LONG-TERM USE OF ANTICYTOKINE THERAPY IN PSORIASIS
- 作者: Kovtunova V.1, Dumchenko V.1,2, Bakhmutova E.1,2, Tkachenko T.2, Yanchevskaya E.1, Mesnyankina O.1
-
隶属关系:
- Astrakhan State Medical University
- Regional Center of Skin and Sexually Transmitted Diseases
- 期: 卷 20, 编号 3 (2017)
- 页面: 163-166
- 栏目: Articles
- URL: https://journals.rcsi.science/1560-9588/article/view/37231
- DOI: https://doi.org/10.18821/1560-9588-2017-20-3-163-166
- ID: 37231
如何引用文章
全文:
详细
作者简介
Violetta Kovtunova
Astrakhan State Medical University
Email: violetta_kovtunova@mail.ru
MD, PhD, Associate Professor of the Department of Dermatovenereology Astrakhan State Medical University. Astrakhan, 414000, Russian Federation. Astrakhan, 414000, Russian Federation
V. Dumchenko
Astrakhan State Medical University; Regional Center of Skin and Sexually Transmitted DiseasesAstrakhan, 414000, Russian Federation; Astrakhan, 414000, Russian Federation
E. Bakhmutova
Astrakhan State Medical University; Regional Center of Skin and Sexually Transmitted DiseasesAstrakhan, 414000, Russian Federation; Astrakhan, 414000, Russian Federation
T. Tkachenko
Regional Center of Skin and Sexually Transmitted DiseasesAstrakhan, 414000, Russian Federation
E. Yanchevskaya
Astrakhan State Medical UniversityAstrakhan, 414000, Russian Federation
O. Mesnyankina
Astrakhan State Medical UniversityAstrakhan, 414000, Russian Federation
参考
- Соколовский Е.В., Круглова Л.С., Понич Е.С. «Болевые» точки системной терапии биологическими препаратами при псориазе. Российский журнал кожных и венерических болезней. 2015; 18(6): 32-8
- Puig L., Thom H., Mollon P., Tian H., Ramakrishna G.S. Clear or almost clear skin improves the quality of life in patients with moderate-to-sever psoriasis: a systematic review and meta-analysis. J. Eur. Academ. Dermatol. Venerol. 2017; 31(2): 213-20. doi: 10.1111/jdv.14007.
- WHO. Global report on psoriasis. 2016. http://apps.who.int/iris/bitstream/10665/204417/1/9789241565189_eng.pdf?ua=1 (accessed 28 July 2016).
- Garcia-Valladares I., Сuchcovich R., Espinosa L.R. Comparative assessment of biologics in treatment of psoriasis: drug design and clinical effectiveness of ustekinumab. Drug Des. Devel. Ther. 2011; 5: 41-9. doi: 10.2147/DDDT.S10494.
- Симбирцев А.С. Цитокины: классификация биологические функции. Цитокины и воспаление. 2004; 3(2): 16-22
- Balding J., Kane D., Livingstone W., Mynett-Johnson L., Bresnihan B., Smith O., Fitz Gerald O. Cytokine gene polymorphism: association with psoriatic arthritis susceptibility and severity. Arth. Rheum. 2003; 48(5): 1408-13.
- Fotiadou C., Lazaridou E., Sotiriou E., Kyrgidis A., Appalla Z., Ioannides D. Scalp psoriasis and biologic agents: a retrospective, comparative study from a tertiary psoriasis referral center. J. Eur. Academ. Dermatol. Venerеol. 2016; 30(12): 2091-6.
- Chong B.F., Wong H.K. Immunobiologics in the treatment of psoriasis. Clin. Immunol. 2007; 123(2): 129-38.
- Barry J., Kirby B. Novel biologic therapies for psoriasis. Expert. Opin. Biol. Ther. 2004; 4(6): 975-87.
- Знаменская Л.Ф. Протеомные технологии в изучении патогенеза псориаза. Вестник дерматологии и венерологии. 2011; 3: 27-33
- Ben-Horis S., Kopylov U., Chowers Y. Optimizing anti-TNF treatments in inflammatory bowel disease. Autoummun. Rev. 2014; 13(1): 24-30
- Тарасено Г.Н., Белякин С.А., Рыжман Н.Н., Кузьмина Ю.В. Антицитокиновая терапия тяжелых форм псориаза. Российский журнал кожных и венерических болезней. 2013; 16(1): 30-3
- Lowes M.A., Bowcock A.M., Krueger J.G. Pathogenesis and therapy of psoriasis. Nature. 2007; 445(7130): 866-72.
- Gudjonsson J.E., Johnston A., Dyson M., Valdimarsson H., Elder J.T. Mouse models of psoriasis. J. Invest. Derm. 2007; 127(6): 1292-308.
- Sano S., Chan K.S., Carbajal S., Clifford J., Peavey M., Kiguchi K., et al. Stat3 links activated keratinocytes and immunocytes required for development of psoriasis in a novel transgenic mouse model. Nat. Med. 2005; 11(1): 43-9.
- Vincent F.B., Morand E.F., Murphy K., Mackay F., Marriette X., Marcelli C. Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralizing agents in chronic inflammatory diseases: a real issue, a clinical perspective. Ann. Rheum. Dis. 2013; 72(2): 165-78.
- Christophers E., Segaert S., Milligan G., Molta C.T., Boggs R. Clinical improvement and satisfaction with biologic therapy in patients with severe plaque psoriasis: results of a European cross-sectional observational study. J. Dermatolog. Treat. 2013; 24(3): 193-8.
- Magis Q., Jullien D., Gaudy-Marqueste C., Baumstark K., Viguier M., Bachelez H., et al.; Groupe de Recherche sur le Psoriasis de la Société Française. Predictors of long-term drugs survival for infliximab in psoriasis. J. Eur. Acad. Dermatol. Venereol. 2017; 31(1): 96-101.
- Катунина О.Р. Роль врожденного и адаптивного иммунитета в патогенезе псориаза. Вестник дерматологии и венерологии. 2009; 5: 43-8.
- Кубанов А.А., Свищенко С.И. Персонализация антицитокиновой терапии больных псориазом. Вестник дерматологии и венерологии. 2015; 1: 54-61.